;PMID: 7693050
;source_file_795.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..165] = [t:36..165]
;2)section:[e:169..204] = [t:169..204]
;3)section:[e:208..283] = [t:208..283]
;4)sentence:[e:287..409] = [t:287..409]
;5)sentence:[e:410..525] = [t:410..525]
;6)sentence:[e:527..676] = [t:527..676]
;7)sentence:[e:678..804] = [t:678..804]
;8)sentence:[e:805..870] = [t:805..870]
;9)sentence:[e:871..957] = [t:871..957]
;10)sentence:[e:958..1049] = [t:958..1049]
;11)sentence:[e:1050..1146] = [t:1050..1146]
;12)sentence:[e:1148..1303] = [t:1148..1303]
;13)sentence:[e:1305..1417] = [t:1305..1417]
;14)sentence:[e:1418..1550] = [t:1418..1550]
;15)sentence:[e:1551..1769] = [t:1551..1769]
;16)sentence:[e:1770..1841] = [t:1770..1841]
;17)sentence:[e:1842..2035] = [t:1842..2035]
;18)section:[e:2039..2083] = [t:2039..2083]

;section 0 Span:0..31
;Blood  1993 Nov 1;82(9):2829-36
(SEC
  (FRAG (RB:[0..5] Blood) (CD:[7..11] 1993) (IN:[12..15] Nov)
        (CD:[16..21] 1;82-LRB-) (CD:[21..22] 9) (-RRB-:[22..23] -RRB-)
        (CD:[23..28] :2829) (::[28..29] -) (CD:[29..31] 36)))

;sentence 1 Span:36..165
;p53 and N-ras mutations in two new leukemia cell lines established from a 
;patient with multilineage CD7-positive acute leukemia.
;[36..39]:gene-rna:"p53"
;[44..49]:gene-rna:"N-ras"
;[71..90]:malignancy:"leukemia cell lines"
;[124..164]:malignancy:"multilineage CD7-positive acute leukemia"
;[137..140]:gene-protein:"CD7"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[36..39] p53)
        (NML-1 (-NONE-:[39..39] *P*)))
      (CC:[40..43] and)
      (NP (NN:[44..49] N-ras)
        (NML-1 (NNS:[50..59] mutations))))
    (PP (IN:[60..62] in)
      (NP
        (NP (CD:[63..66] two) (JJ:[67..70] new)
           (NN:[71..79] leukemia) (NN:[80..84] cell) (NNS:[85..90] lines))
        (VP (VBN:[91..102] established)
          (NP (-NONE-:[102..102] *))
          (PP (IN:[103..107] from)
            (NP
              (NP (DT:[108..109] a) (NN:[111..118] patient))
              (PP (IN:[119..123] with)
                (NP (JJ:[124..136] multilineage)
                  (ADJP (NN:[137..140] CD7) (HYPH:[140..141] -)
                        (JJ:[141..149] positive))
                  (JJ:[150..155] acute) (NN:[156..164] leukemia))))))))
    (.:[164..165] .)))

;section 2 Span:169..204
;Abo J, Inokuchi K, Dan K, Nomura T.
(SEC
  (FRAG (NNP:[169..172] Abo) (NNP:[173..175] J,) (NNP:[176..184] Inokuchi)
        (NNP:[185..186] K) (NNP:[186..187] ,) (NNP:[188..191] Dan)
        (NNP:[192..193] K) (,:[193..194] ,) (NNP:[195..201] Nomura)
        (NNP:[202..204] T.)))

;section 3 Span:208..283
;Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
(SEC
  (FRAG (NNP:[208..213] Third) (NNP:[214..224] Department) (IN:[225..227] of)
        (NNP:[228..236] Internal) (NNP:[237..245] Medicine) (,:[245..246] ,)
        (NNP:[247..253] Nippon) (NNP:[254..261] Medical) (NNP:[262..268] School)
        (,:[268..269] ,) (NNP:[270..275] Tokyo) (,:[275..276] ,)
        (NNP:[277..282] Japan) (.:[282..283] .)))

;sentence 4 Span:287..409
;Two new myeloid cell lines (K051 and K052) were established from a patient
;with  multilineage CD7-positive acute leukemia.
;[295..313]:malignancy:"myeloid cell lines"
;[315..319]:malignancy:"K051"
;[324..328]:malignancy:"K052"
;[368..408]:malignancy:"multilineage CD7-positive acute leukemia"
;[381..384]:gene-protein:"CD7"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[287..290] Two) (JJ:[291..294] new)
         (JJ:[295..302] myeloid) (NN:[303..307] cell) (NNS:[308..313] lines))
      (NP (-LRB-:[314..315] -LRB-) (NN:[315..319] K051) (CC:[320..323] and)
          (NN:[324..328] K052) (-RRB-:[328..329] -RRB-)))
    (VP (VBD:[330..334] were)
      (VP (VBN:[335..346] established)
        (NP-1 (-NONE-:[346..346] *))
        (PP (IN:[347..351] from)
          (NP
            (NP (DT:[352..353] a) (NN:[354..361] patient))
            (PP (IN:[362..366] with)
              (NP (JJ:[368..380] multilineage)
                (ADJP (NN:[381..384] CD7) (HYPH:[384..385] -)
                      (JJ:[385..393] positive))
                (JJ:[394..399] acute) (NN:[400..408] leukemia)))))))
    (.:[408..409] .)))

;sentence 5 Span:410..525
;The K051 and K052 were established  from the patient's bone marrow cells at
;diagnosis and at relapse, respectively.
;[414..418]:malignancy:"K051"
;[423..427]:malignancy:"K052"
(SENT
  (S
    (NP-SBJ-1 (DT:[410..413] The) (NN:[414..418] K051) (CC:[419..422] and)
              (NN:[423..427] K052))
    (VP (VBD:[428..432] were)
      (VP (VBN:[433..444] established)
        (NP-1 (-NONE-:[444..444] *))
        (PP (IN:[446..450] from)
          (NP
            (NP (DT:[451..454] the) (NN:[455..462] patient) (POS:[462..464] 's))
            (NN:[465..469] bone) (NN:[470..476] marrow) (NNS:[477..482] cells)))
        (PP-TMP
          (PP (IN:[483..485] at)
            (NP (NN:[486..495] diagnosis)))
          (CC:[496..499] and)
          (PP (IN:[500..502] at)
            (NP (NN:[503..510] relapse))))
        (,:[510..511] ,)
        (ADVP (RB:[512..524] respectively))))
    (.:[524..525] .)))

;sentence 6 Span:527..676
;The K051 cell expressed myeloid-associated antigens (CD13 and CD33), a 
;platelet-associated antigen (CD41), and an erythroid antigen (glycophorin
;A).
;[531..540]:malignancy:"K051 cell"
;[551..578]:gene-protein:"myeloid-associated antigens"
;[580..584]:gene-protein:"CD13"
;[589..593]:gene-protein:"CD33"
;[599..626]:gene-protein:"platelet-associated antigen"
;[628..632]:gene-protein:"CD41"
;[642..659]:gene-protein:"erythroid antigen"
;[661..674]:gene-protein:"glycophorin A"
(SENT
  (S
    (NP-SBJ (DT:[527..530] The)
       (NN:[531..535] K051) (NN:[536..540] cell))
    (VP (VBD:[541..550] expressed)
      (NP
        (NP
          (NP
            (ADJP (NN:[551..558] myeloid) (HYPH:[558..559] -)
                  (JJ:[559..569] associated))
            (NNS:[570..578] antigens))
          (NP (-LRB-:[579..580] -LRB-) (NN:[580..584] CD13) (CC:[585..588] and)
              (NN:[589..593] CD33) (-RRB-:[593..594] -RRB-)))
        (,:[594..595] ,)
        (NP
          (NP (DT:[596..597] a)
            
            (ADJP (NN:[599..607] platelet) (HYPH:[607..608] -)
                  (JJ:[608..618] associated))
            (NN:[619..626] antigen))
          (NP (-LRB-:[627..628] -LRB-) (NN:[628..632] CD41)
              (-RRB-:[632..633] -RRB-)))
        (,:[633..634] ,) (CC:[635..638] and)
        (NP
          (NP (DT:[639..641] an)
             (JJ:[642..651] erythroid) (NN:[652..659] antigen))
          (NP (-LRB-:[660..661] -LRB-)
             (NN:[661..672] glycophorin) (NN:[673..674] A)
            (-RRB-:[674..675] -RRB-)))))
    (.:[675..676] .)))

;sentence 7 Span:678..804
;The K052 cell expressed myeloid-associated antigens (CD13, CD14, and CD33), 
;lymphoid markers (CD2, CD5, and CD7), and HLA-DR.
;[682..691]:malignancy:"K052 cell"
;[702..729]:gene-protein:"myeloid-associated antigens"
;[731..735]:gene-protein:"CD13"
;[737..741]:gene-protein:"CD14"
;[747..751]:gene-protein:"CD33"
;[755..771]:gene-protein:"lymphoid markers"
;[773..776]:gene-protein:"CD2"
;[778..781]:gene-protein:"CD5"
;[787..790]:gene-protein:"CD7"
;[797..803]:gene-protein:"HLA-DR"
(SENT
  (S
    (NP-SBJ (DT:[678..681] The)
       (NN:[682..686] K052) (NN:[687..691] cell))
    (VP (VBD:[692..701] expressed)
      (NP
        (NP
          
          (ADJP (NN:[702..709] myeloid) (HYPH:[709..710] -)
                (JJ:[710..720] associated))
          (NNS:[721..729] antigens)
          (PRN (-LRB-:[730..731] -LRB-)
            (NP (NN:[731..735] CD13) (,:[735..736] ,) (NN:[737..741] CD14)
                (,:[741..742] ,) (CC:[743..746] and) (NN:[747..751] CD33))
            (-RRB-:[751..752] -RRB-)))
        (,:[752..753] ,)
        (NP
           (JJ:[755..763] lymphoid) (NNS:[764..771] markers)
          (PRN (-LRB-:[772..773] -LRB-)
            (NP (NN:[773..776] CD2) (,:[776..777] ,) (NN:[778..781] CD5)
                (,:[781..782] ,) (CC:[783..786] and) (NN:[787..790] CD7))
            (-RRB-:[790..791] -RRB-)))
        (,:[791..792] ,) (CC:[793..796] and)
        (NP (NN:[797..803] HLA-DR))))
    (.:[803..804] .)))

;sentence 8 Span:805..870
;Chromosome analysis of both  cell lines showed a 17p- chromosome.
;[834..844]:malignancy:"cell lines"
;[854..869]:variation-location:"17p- chromosome"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[805..815] Chromosome) (NN:[816..824] analysis))
      (PP (IN:[825..827] of)
        (NP (DT:[828..832] both)
           (NN:[834..838] cell) (NNS:[839..844] lines))))
    (VP (VBD:[845..851] showed)
      (NP (DT:[852..853] a)
         (NN:[854..857] 17p) (SYM:[857..858] -) (NN:[859..869] chromosome)))
    (.:[869..870] .)))

;sentence 9 Span:871..957
;Both cell lines were investigated for  aberrations of the p53 gene and the
;N-ras gene.
;[876..886]:malignancy:"cell lines"
;[929..932]:gene-rna:"p53"
;[946..951]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-1 (DT:[871..875] Both)
       (NN:[876..880] cell) (NNS:[881..886] lines))
    (VP (VBD:[887..891] were)
      (VP (VBN:[892..904] investigated)
        (NP-1 (-NONE-:[904..904] *))
        (PP (IN:[905..908] for)
          (NP
            (NP (NNS:[910..921] aberrations))
            (PP (IN:[922..924] of)
              (NP
                (NP (DT:[925..928] the) (NN:[929..932] p53) (NN:[933..937] gene))
                (CC:[938..941] and)
                (NP (DT:[942..945] the) (NN:[946..951] N-ras)
                    (NN:[952..956] gene))))))))
    (.:[956..957] .)))

;sentence 10 Span:958..1049
;A p53 mutation detected in both  cell lines consisted of a C-->T substitution
;in codon 248.
;[960..963]:gene-rna:"p53"
;[964..972]:variation-event:"mutation"
;[991..1001]:malignancy:"cell lines"
;[1017..1018]:variation-state-original:"C"
;[1021..1022]:variation-state-altered:"T"
;[1023..1035]:variation-type:"substitution"
;[1039..1048]:variation-location:"codon 248"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[958..959] A) (NN:[960..963] p53) (NN:[964..972] mutation))
      (VP (VBN:[973..981] detected)
        (NP (-NONE-:[981..981] *))
        (PP (IN:[982..984] in)
          (NP (DT:[985..989] both)
             (NN:[991..995] cell) (NNS:[996..1001] lines)))))
    (VP (VBD:[1002..1011] consisted)
      (PP-CLR (IN:[1012..1014] of)
        (NP
          (NP (DT:[1015..1016] a)
            (NML
              (NML (NN:[1017..1018] C))
              (PP (SYM:[1018..1021] -->)
                (NP (NN:[1021..1022] T))))
            (NN:[1023..1035] substitution))
          (PP-LOC (IN:[1036..1038] in)
            (NP (NN:[1039..1044] codon) (CD:[1045..1048] 248))))))
    (.:[1048..1049] .)))

;sentence 11 Span:1050..1146
;An N-ras mutation  detected only in the K052 cell consisted of a G-->C
;substitution in codon 13.
;[1053..1058]:gene-rna:"N-ras"
;[1059..1067]:variation-event:"mutation"
;[1090..1099]:malignancy:"K052 cell"
;[1115..1116]:variation-state-original:"G"
;[1119..1120]:variation-state-altered:"C"
;[1121..1133]:variation-type:"substitution"
;[1137..1145]:variation-location:"codon 13"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1050..1052] An) (NN:[1053..1058] N-ras)
          (NN:[1059..1067] mutation))
      (VP (VBN:[1069..1077] detected)
        (NP (-NONE-:[1077..1077] *))
        (PP-LOC (RB:[1078..1082] only) (IN:[1083..1085] in)
          (NP (DT:[1086..1089] the)
             (NN:[1090..1094] K052) (NN:[1095..1099] cell)))))
    (VP (VBD:[1100..1109] consisted)
      (PP-CLR (IN:[1110..1112] of)
        (NP
          (NP (DT:[1113..1114] a)
            (NML
              (NML (NN:[1115..1116] G))
              (PP (SYM:[1116..1119] -->)
                (NP (NN:[1119..1120] C))))
            (NN:[1121..1133] substitution))
          (PP-LOC (IN:[1134..1136] in)
            (NP (NN:[1137..1142] codon) (CD:[1143..1145] 13))))))
    (.:[1145..1146] .)))

;sentence 12 Span:1148..1303
;Expression of the multidrug resistance gene (MDR1) was also investigated by
;the  semiquantitative reverse transcriptase-polymerase chain reaction
;(RT-PCR).
;[1166..1191]:gene-rna:"multidrug resistance gene"
;[1193..1197]:gene-rna:"MDR1"
;[1246..1267]:gene-protein:"reverse transcriptase"
;[1268..1278]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1148..1158] Expression))
      (PP (IN:[1159..1161] of)
        (NP
          (NP (DT:[1162..1165] the)
             (JJ:[1166..1175] multidrug) (NN:[1176..1186] resistance)
             (NN:[1187..1191] gene))
          (NP (-LRB-:[1192..1193] -LRB-) (NN:[1193..1197] MDR1)
              (-RRB-:[1197..1198] -RRB-)))))
    (VP (VBD:[1199..1202] was)
      (ADVP (RB:[1203..1207] also))
      (VP (VBN:[1208..1220] investigated)
        (NP-1 (-NONE-:[1220..1220] *))
        (PP-MNR (IN:[1221..1223] by)
          (NP (DT:[1224..1227] the) (JJ:[1229..1245] semiquantitative)
            (NML
              (NML
                (NML (JJ:[1246..1253] reverse) (NN:[1254..1267] transcriptase))
                (HYPH:[1267..1268] -)
                (NML (NN:[1268..1278] polymerase) (NN:[1279..1284] chain)
                     (NN:[1285..1293] reaction)))
              (NML (-LRB-:[1294..1295] -LRB-) (NN:[1295..1297] RT)
                   (HYPH:[1297..1298] -) (NN:[1298..1301] PCR)
                   (-RRB-:[1301..1302] -RRB-)))))))
    (.:[1302..1303] .)))

;sentence 13 Span:1305..1417
;MDR1-mRNA was more highly expressed by the K052 cell than the K051 cell,
;being  equivalent to that in HEL cells.
;[1305..1309]:gene-rna:"MDR1"
;[1348..1357]:malignancy:"K052 cell"
;[1367..1376]:malignancy:"K051 cell"
;[1407..1416]:malignancy:"HEL cells"
(SENT
  (S
    (NP-SBJ-1 (NN:[1305..1309] MDR1) (HYPH:[1309..1310] -)
              (NN:[1310..1314] mRNA))
    (VP (VBD:[1315..1318] was)
      (VP
        (ADVP
          (ADVP (RBR:[1319..1323] more) (RB:[1324..1330] highly))
          (PP-2 (-NONE-:[1330..1330] *ICH*)))
        (VBN:[1331..1340] expressed)
        (NP-1 (-NONE-:[1340..1340] *))
        (PP (IN:[1341..1343] by)
          (NP-LGS (DT:[1344..1347] the)
             (NN:[1348..1352] K052) (NN:[1353..1357] cell)))
        (PP-2 (IN:[1358..1362] than)
          (NP (DT:[1363..1366] the)
             (NN:[1367..1371] K051) (NN:[1372..1376] cell)))
        (,:[1376..1377] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1377..1377] *))
          (VP (VBG:[1378..1383] being)
            (ADJP-PRD (JJ:[1385..1395] equivalent)
              (PP (TO:[1396..1398] to)
                (NP
                  (NP (DT:[1399..1403] that))
                  (PP-LOC (IN:[1404..1406] in)
                    (NP (NN:[1407..1410] HEL) (NNS:[1411..1416] cells))))))))))
    (.:[1416..1417] .)))

;sentence 14 Span:1418..1550
;The functional MDR1-protein against vincristine  was also observed, and its
;function was inhibited by verapamile and Cyclosporin  A.
;[1433..1437]:gene-protein:"MDR1"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (DT:[1418..1421] The) (JJ:[1422..1432] functional)
            (NN:[1433..1437] MDR1) (HYPH:[1437..1438] -)
            (NN:[1438..1445] protein))
        (PP (IN:[1446..1453] against)
          (NP (NN:[1454..1465] vincristine))))
      (VP (VBD:[1467..1470] was)
        (ADVP (RB:[1471..1475] also))
        (VP (VBN:[1476..1484] observed)
          (NP-2 (-NONE-:[1484..1484] *)))))
    (,:[1484..1485] ,) (CC:[1486..1489] and)
    (S
      (NP-SBJ-1 (PRP$:[1490..1493] its) (NN:[1494..1502] function))
      (VP (VBD:[1503..1506] was)
        (VP (VBN:[1507..1516] inhibited)
          (NP-1 (-NONE-:[1516..1516] *))
          (PP (IN:[1517..1519] by)
            (NP-LGS
              (NP (NN:[1520..1530] verapamile))
              (CC:[1531..1534] and)
              (NP (NN:[1535..1546] Cyclosporin) (NN:[1548..1549] A)))))))
    (.:[1549..1550] .)))

;sentence 15 Span:1551..1769
;The K052 cells were capable of phenotypic or morphologic differentiation 
;after being incubated with granulocyte colony-stimulating factor,
;interleukin-2,  phorbol 12-myristate 13-acetate, or 1,25-dihydroxy-vitamin
;D3.
;[1555..1565]:malignancy:"K052 cells"
;[1652..1689]:gene-protein:"granulocyte colony-stimulating factor"
;[1691..1704]:gene-protein:"interleukin-2"
(SENT
  (S
    (NP-SBJ (DT:[1551..1554] The)
       (NN:[1555..1559] K052) (NNS:[1560..1565] cells))
    (VP (VBD:[1566..1570] were)
      (ADJP-PRD (JJ:[1571..1578] capable)
        (PP (IN:[1579..1581] of)
          (NP
            (NP (JJ:[1582..1592] phenotypic)
              (NML-2 (-NONE-:[1592..1592] *P*)))
            (CC:[1593..1595] or)
            (NP (JJ:[1596..1607] morphologic)
              (NML-2 (NN:[1608..1623] differentiation))))))
      (PP-TMP (IN:[1625..1630] after)
        (S-NOM
          (NP-SBJ-1 (-NONE-:[1630..1630] *))
          (VP (VBG:[1631..1636] being)
            (VP (VBN:[1637..1646] incubated)
              (NP-1 (-NONE-:[1646..1646] *))
              (PP (IN:[1647..1651] with)
                (NP
                  (NP (NN:[1652..1663] granulocyte)
                    (ADJP (NN:[1664..1670] colony) (HYPH:[1670..1671] -)
                          (VBG:[1671..1682] stimulating))
                    (NN:[1683..1689] factor))
                  (,:[1689..1690] ,)
                  (NP (NN:[1691..1704] interleukin-2))
                  (,:[1704..1705] ,)
                  (NP (NN:[1707..1714] phorbol) (NN:[1715..1727] 12-myristate)
                      (NN:[1728..1738] 13-acetate))
                  (,:[1738..1739] ,) (CC:[1740..1742] or)
                  (NP (NN:[1743..1765] 1,25-dihydroxy-vitamin)
                      (NN:[1766..1768] D3)))))))))
    (.:[1768..1769] .)))

;sentence 16 Span:1770..1841
;In contrast, the  K051 cells responded phenotypically to retinoic acid.
;[1788..1798]:malignancy:"K051 cells"
(SENT
  (S
    (PP (IN:[1770..1772] In)
      (NP (NN:[1773..1781] contrast)))
    (,:[1781..1782] ,)
    (NP-SBJ (DT:[1783..1786] the)
       (NN:[1788..1792] K051) (NNS:[1793..1798] cells))
    (VP (VBD:[1799..1808] responded)
      (ADVP (RB:[1809..1823] phenotypically))
      (PP-CLR (TO:[1824..1826] to)
        (NP (JJ:[1827..1835] retinoic) (NN:[1836..1840] acid))))
    (.:[1840..1841] .)))

;sentence 17 Span:1842..2035
;Thus, the K051 and K052  cell lines will be useful for investigating the
;cellular and molecular events in  leukemogenesis and differentiation, and the
;mechanism of expression of the MDR1  gene.
;[1852..1856]:malignancy:"K051"
;[1861..1877]:malignancy:"K052  cell lines"
;[2024..2028]:gene-rna:"MDR1"
(SENT
  (S
    (ADVP (RB:[1842..1846] Thus))
    (,:[1846..1847] ,)
    (NP-SBJ (DT:[1848..1851] the)
      (NML
        (NML (NN:[1852..1856] K051)
          (NML-2 (-NONE-:[1856..1856] *P*)))
        (CC:[1857..1860] and)
        (NML (NN:[1861..1865] K052)
          (NML-2 (NN:[1867..1871] cell) (NNS:[1872..1877] lines)))))
    (VP (MD:[1878..1882] will)
      (VP (VB:[1883..1885] be)
        (ADJP-PRD (JJ:[1886..1892] useful)
          (PP (IN:[1893..1896] for)
            (S-NOM
              (NP-SBJ (-NONE-:[1896..1896] *))
              (VP (VBG:[1897..1910] investigating)
                (NP
                  (NP
                    (NP (DT:[1911..1914] the)
                      (NML
                        (NML (JJ:[1915..1923] cellular)
                          (NML-1 (-NONE-:[1923..1923] *P*)))
                        (CC:[1924..1927] and)
                        (NML (JJ:[1928..1937] molecular)
                          (NML-1 (NNS:[1938..1944] events)))))
                    (PP (IN:[1945..1947] in)
                      (NP (NN:[1949..1963] leukemogenesis) (CC:[1964..1967] and)
                          (NN:[1968..1983] differentiation))))
                  (,:[1983..1984] ,) (CC:[1985..1988] and)
                  (NP
                    (NP (DT:[1989..1992] the) (NN:[1993..2002] mechanism))
                    (PP (IN:[2003..2005] of)
                      (NP
                        (NP (NN:[2006..2016] expression))
                        (PP (IN:[2017..2019] of)
                          (NP (DT:[2020..2023] the) (NN:[2024..2028] MDR1)
                              (NN:[2030..2034] gene)))))))))))))
    (.:[2034..2035] .)))

;section 18 Span:2039..2083
;PMID: 7693050 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2039..2043] PMID) (::[2043..2044] :) (CD:[2045..2052] 7693050)
        (NN:[2053..2054] -LSB-) (NNP:[2054..2060] PubMed) (::[2061..2062] -)
        (NN:[2063..2070] indexed) (IN:[2071..2074] for)
        (NNP:[2075..2083] MEDLINE-RSB-)))
